David Shaw’s Evolent Health EVH Stock Holding History

David Shaw’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20,000	Closed	-$553K	–	5642
2021 Q4	$553K	Hold	20,000	–	–	﹤0.01%	4346
2021 Q3	$620K	Buy	+20,000	New	+$480K	﹤0.01%	3952

Other funds holding EVH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's EVH Position: Q2 2026 in Review

David Shaw reduced its Evolent Health (EVH) stake by 6% in Q2 2026, selling an estimated $1.25M and leaving 5,107,561 shares worth $27.7M. The position accounts for 0.01% of the portfolio, ranked #1086.

David Shaw first reported a position in EVH in Q3 2015 and has held it in 29 quarters since. 199 funds tracked by Wall St. Rank hold EVH as of Q2 2026.

David Shaw held 5,107,561 shares of Evolent Health worth $27.7M as of Q2 2026.
David Shaw sold 326,471 Evolent Health shares in Q2 2026, an estimated $1.25M.
Evolent Health made up 0.01% of David Shaw's portfolio in Q2 2026, its #1086 holding.
David Shaw first reported a position in Evolent Health in Q3 2015 and has held it in 29 quarters since.
199 funds tracked by Wall St. Rank held Evolent Health as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.